Efficacy and safety of erlotinib versus chemotherapy in second-line advanced non-small-cell lung cancer (nsclc) with poor prognosis: The phase III Titan study

dc.contributor.author	Ciuleanu, Tudor
dc.contributor.author	Stelmakh, Lilia
dc.contributor.author	Cicenas, S.
dc.contributor.author	Esteban González, Emilio
dc.date.accessioned	2014-03-14T07:42:41Z
dc.date.available	2014-03-14T07:42:41Z
dc.date.issued	2011
dc.identifier.citation	Lung Cancer, 71, p. S44-S44 (2011); doi:10.1016/S0169-5002(11)70225-2
dc.identifier.issn	0169-5002
dc.identifier.uri	http://hdl.handle.net/10651/23995
dc.format.extent	p. S44-S44
dc.language.iso	eng
dc.relation.ispartof	Lung Cancer
dc.rights	© 2011 Elsevier Ireland Ltd.
dc.source	WOS
dc.title	Efficacy and safety of erlotinib versus chemotherapy in second-line advanced non-small-cell lung cancer (nsclc) with poor prognosis: The phase III Titan study
dc.type	journal article
dc.identifier.local	20140894
dc.identifier.doi	10.1016/S0169-5002(11)70225-2
dc.relation.publisherversion	http://dx.doi.org/10.1016/S0169-5002(11)70225-2

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.